Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Astrocytoma (grade III) are frequently mutated in isocitrate dehydrogenase (IDH1).
|
31039537 |
2019 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We here report neuroimaging findings in a 69-year-old man with a "butterfly" pattern on dynamic FET [O-(2-[F]-fluoroethyl)-L-tyrosine] PET and the diagnosis of an anaplastic astrocytoma (WHO grade III; IDH-1/-2 wildtype, no 1p/19q co-deletion) but without typical MRI contrast enhancement.
|
31348085 |
2019 |
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma.
|
31371189 |
2019 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An important underlying observation was that patients with anaplastic astrocytomas (AA) without IDH mutation had a clinical course similar to that of patients with glioblastomas (GBM).
|
31623667 |
2019 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype.
|
30878754 |
2019 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutated IDH1 R132H protein was expressed in 2 GBM from adult patients with previous supratentorial anaplastic astrocytoma.
|
30203362 |
2018 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis demonstrated that T2-EOR (HR 3.28; 95% CI 1.22-8.81; p = 0.0192) and IDH1 mutation (HR 3.90; 95% CI 1.53-10.75; p = 0.0044) were predictive of survival in patients with AA and AOA.
|
28885120 |
2018 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors.
|
30072066 |
2018 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
33-year-old nulligravid woman with newly diagnosed anaplastic astrocytoma (AA; WHO grade III, IDH1-negative) sought fertility preservation.
|
29739361 |
2018 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The histopathologic examination confirmed a leptomeningeal spread of a K27M-mutated anaplastic astrocytoma (WHO° III) without R132H-IDH1 mutation.
|
29066318 |
2018 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Volumetric, T1-weighted MRI scans were obtained retrospectively from 35 patients with IDH1 mutant and 32 patients with wild type malignant astrocytoma (mean age = 45 ± 14 years) and used to extract individual level, gray matter connectomes.
|
27848136 |
2017 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Diffuse astrocytoma (DA), anaplastic astrocytoma (AA), and glioblastoma (GBM) are defined by the World Health Organization (WHO) based on IDH-mutational status.
|
28110298 |
2017 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The R132H mutation in IDH1 was found in 60.5% (23/38) of patients in the AA cohort (Groups 2 and 4) and 20.0% (13/65) of patients from our GBM cohort (Groups 3 and 5), whereas all patients with ODG (Group 1) had a mutation either in IDH1 (n = 62) or IDH2 (n = 3).
|
28851427 |
2017 |
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors.
|
28640702 |
2017 |
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among IDH1-mutated astrocytomas no significant difference in survival was shown between DA and AA.
|
28214203 |
2017 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast, high expression of PROX1 protein predicted shorter survival in the group of patients with IDH-mutant anaplastic astrocytomas and secondary glioblastomas.
|
27626492 |
2016 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A second surgery was performed, and pathology demonstrated recurrent tumor, consistent with IDH1-mutated anaplastic astrocytoma.
|
26911558 |
2016 |
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The majority of glioblastomas develop rapidly with a short clinical history (primary glioblastoma IDH wild-type), whereas secondary glioblastomas progress from diffuse astrocytoma or anaplastic astrocytoma.
|
26443480 |
2016 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
|
25962792 |
2015 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The JHH-273 model is characteristic of anaplastic astrocytoma and represents a valuable tool for investigating the pathogenesis of this distinct molecular subset of gliomas and for preclinical testing of compounds targeting IDH1 mutations or alternative lengthening of telomeres.
|
25471051 |
2015 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
|
24748470 |
2014 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene.
|
24149775 |
2014 |
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas-World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.
|
24305719 |
2014 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IHC detected the IDH1 mutation in 72% (13/18) anaplastic astrocytomas and 30% (3/10) astrocytomas; however, it failed to detect the mutation in 258 thyroid, 11 renal cell, 10 ovarian, 18 endometrial, 20 breast, 25 colorectal, 22 non-small cell lung carcinoma, 25 melanomas, and 8 thyroid follicular adenomas.
|
23235339 |
2014 |
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.
|
24777756 |
2014 |